FIA
RNXT icon

FNY Investment Advisers’s RenovoRx RNXT Stock Holding History

FNY Investment Advisers’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,700
Closed -$3K – 1043
2025
Q4 		$3K Sell
3,700
-12,300
-77% -$12.3K ﹤0.01% 786
2025
Q3 		$20K Buy
+16,000
New +$19K 0.01% 684

Other funds holding RNXT

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
NPT
Nixon Peabody Trust Boston, Massachusetts $1.26B AUM 24.14% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return

FNY Investment Advisers's RNXT Position: Q1 2026 in Review

FNY Investment Advisers sold out of RenovoRx (RNXT) in Q1 2026, closing a stake of 3,700 shares — an estimated $3K sold.

FNY Investment Advisers first reported a position in RNXT in Q3 2025 and held it in 2 quarters. The position peaked at $20K in Q3 2025. 31 funds tracked by Wall St. Rank hold RNXT as of Q1 2026.

  • FNY Investment Advisers reported no remaining RenovoRx position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 3,700 RenovoRx shares in Q1 2026, an estimated $3K.
  • FNY Investment Advisers first reported a position in RenovoRx in Q3 2025 and held it in 2 quarters.
  • FNY Investment Advisers's RenovoRx position peaked at $20K in Q3 2025.
  • 31 funds tracked by Wall St. Rank held RenovoRx as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.